腹腔镜远端胰腺切除术治疗胰腺癌安全有效
腹腔镜组出血量更少、输血更少、阳性淋巴结更少、C型胰瘘更少,复发和生存无统计学差异。结论认为腹腔镜远端胰腺切除术安全且肿瘤学结局与开腹相当。
要点
- 腹腔镜远端胰腺切除术治疗胰腺导管腺癌的短期结局优于开腹手术。
- 腹腔镜组出血量、输血需求、阳性淋巴结数和C型胰瘘发生率均更低。
- 两组复发率和生存率无统计学差异,肿瘤学结局相当。
核心结论
- 腹腔镜远端胰腺切除术是安全的手术方式,肿瘤学结局与开腹远端胰腺切除术相当。
研究设计与样本
- 单中心高容量机构10年(2005-2014)连续远端胰腺切除术422例的回顾性分析。
主要发现
- 腹腔镜组与开腹组在人口学、BMI和ASA分级无统计学差异。
- 腹腔镜组出血量更低(310±68 vs. 597±95 ml,P=0.016),输血更少(0 vs. 13,P=0.0008)。
- 腹腔镜组阳性淋巴结更少(0.8±0.2 vs. 1.6±0.3,P=0.04),C型胰瘘发生率更低(0 vs. 13%,P=0.03)。
- 两组远端或局部复发(30% vs. 52%,P=0.05)和中位生存(18 vs. 15个月)无统计学差异。
- 腹腔镜组与开腹组1年(73% vs. 59%)、3年(22% vs. 21%)、5年(20% vs. 15%)生存率相近。
临床怎么用
- 对于胰腺导管腺癌行远端胰腺切除术,腹腔镜 approach 可考虑作为安全选择,短期结局可能更优。
- 需结合肿瘤大小、淋巴结清扫和切缘状态等肿瘤学指标综合评估腹腔镜手术的适用性。
局限性
- 中位随访仅11.4个月,长期肿瘤学结局需更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the short-term and oncologic outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) undergoing laparoscopic distal pancreatectomy (LDP) and open distal pancreatectomy (ODP). METHODS: Consecutive cases of distal pancreatectomy (DP) (n = 422) were reviewed at a single high-volume institution over a 10-year period (2005-2014). Inclusion criteria consisted of any patient with PDAC by surgical pathology. Ninety-day outcomes were monitored through a prospectively maintained pancreatic resection database. The Social Security Death Index was used for 5-year survival. Two-way statistical analyses were used to compare categories; variance was reported with standard error of the mean; * indicates P value <0.05. RESULTS: Seventy-nine patients underwent DP for PDAC. Thirty-three underwent LDP and 46 ODP. There were no statistical differences in demographics, BMI, and ASA classification. Intraoperative and surgical pathology variables were comparable for LDP versus ODP: operative time (3.9 ± 0.2 vs. 4.2 ± 0.2 h), duct size, gland texture, stump closure, tumor size (3.3 ± 0.3 vs. 4.0 ± 0.4 cm), lymph node harvest (14.5 ± 1.1 vs. 17.5 ± 1.2), tumor stage (see table), and negative surgical margins (77 vs. 87%). Patients who underwent LDP experienced lower blood loss (310 ± 68 vs. 597 ± 95 ml; P = 0.016*) and required fewer transfusions (0 vs. 13; P = 0.0008*). Patients who underwent LDP had fewer positive lymph nodes (0.8 ± 0.2 vs. 1.6 ± 0.3; P = 0.04*) and a lower incidence of type C pancreatic fistula (0 vs. 13%; P = 0.03*). Median follow-up for all patients was 11.4 months. Long-term oncologic outcomes revealed similar outcomes including distant or local recurrence (30 vs. 52%; P = 0.05) and median survival (18 vs. 15 months), as well as 1-year (73 vs. 59%), 3-year (22 vs. 21%), and 5-year (20 vs. 15%) survival for LDP and ODP, respectively. CONCLUSIONS: The results of this series suggest that LDP is a safe surgical approach that is comparable from an oncologic standpoint to ODP for the management of pancreatic adenocarcinoma.
引用
- Bauman MD, Becerra DG, Kilbane EM, et al. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. Surg Endosc. 2017. PMID: 28643065. doi:10.1007/s00464-017-5633-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。